Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia in Patients with Moderately to Severely Active Ulcerative Colitis Pharmaceutical Investing
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor Pharmaceutical Investing
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy Pharmaceutical Investing
Johnson & Johnson Names Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors Pharmaceutical Investing
Pfizer and OPKO's Once-Weekly NGENLA Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency Life Science Investing
European Medicines Agency Approves Pfizer's 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults Life Science Investing
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion Pharmaceutical Investing
